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Abstract
Cilostazol, a type-3 phosphodiesterase (PDE3) inhibitor, has become widely used as an antiplatelet drug worldwide. A recent
second Cilostazol Stroke Prevention Study demonstrated that cilostazol is superior to aspirin for prevention of stroke after
an ischemic stroke. However, its precise mechanisms of action remain to be determined. Here, we report that cilostazol, but
not the PDE3 inhibitors cilostamide and milrinone, significantly potentiated nerve growth factor (NGF)-induced neurite
outgrowth in PC12 cells. Furthermore, specific inhibitors for the endoplasmic reticulum protein inositol 1,4,5-triphosphate
(IP3) receptors and several common signaling pathways (PLC-c, PI3K, Akt, p38 MAPK, and c-Jun N-terminal kinase (JNK), and
the Ras/Raf/ERK/MAPK) significantly blocked the potentiation of NGF-induced neurite outgrowth by cilostazol. Using a
proteomics analysis, we identified that levels of eukaryotic translation elongation factor eEF1A1 protein were significantly
increased by treatment with cilostazol, but not cilostamide, in PC12 cells. Moreover, the potentiating effects of cilostazol on
NGF-induced neurite outgrowth were significantly antagonized by treatment with eEF1A1 RNAi, but not the negative
control of eEF1A1. These findings suggest that eEF1A1 and several common cellular signaling pathways might play a role in
the mechanism of cilostazol-induced neurite outgrowth. Therefore, agents that can increase the eEF1A1 protein may have
therapeutic relevance in diverse conditions with altered neurite outgrowth.
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Introduction
Cilostazol, a potent inhibitor of phosphodiesterase type-3
(PDE3), is an antiplatelet/ antithrombotic agent used worldwide
for the treatment of chronic arterial occlusion and intermittent
claudication with peripheral occlusion and used in Japan and some
other Asian countries for the prevention of ischemic stroke [1–4].
The Cilostazol Stroke Prevention Study demonstrated that
cilostazol significantly reduced the incidence of secondary stroke
in patients with recent stroke or transient ischemic attack [5,6].
Furthermore, subgroup analysis of this study showed that
cilostazol is also useful in preventing the recurrence of vascular
events in patients with lacunar infarction, and is probably effective
in high-risk patients with diabetes and/or hypertension [7]. A
meta-analysis of placebo-controlled randomized trials of cilostazol
in patients with atherothrombosis demonstrated a significant risk
reduction for cerebrovascular events, with no associated increase
of bleeding risk [8]. Moreover, a randomized, double-blind study
of cilostazol and aspirin demonstrated that cilostazol might be
more effective and safe than aspirin for Chinese patients with
ischemic stroke [9,10]. The multicenter double-blind placebo-
controlled trial showed that cilostazol prevents the progression of
symptomatic intracranial arterial stenosis [11]. Very recently, the
second Cilostazol Stroke Prevention Study demonstrated that
cilostazol might be superior to aspirin for prevention of stroke after
an ischemic stroke [12]. Taken together, these findings suggest
that inhibition of PDE3 by cilostazol may contribute to its
beneficial effects in these diseases although the precise mechanisms
underlying the beneficial effects of cilostazol are not fully
understood.
Recently, we reported that cilostazol was effective for both N-
methyl-D-aspartate (NMDA) receptor antagonist phencyclidine-
induced cognitive deficits and NMDA receptor antagonist
dizocilpine-induced prepulse inhibition deficits in mice, suggesting
that cilostazol has potential antipsychotic activity [13,14]. There
are also case reports showing that augmentation therapy with
cilostazol improved the depressive symptoms in patients with
geriatric depression [15,16] and cognitive impairments in patients
with moderate Alzheimer disease [17]. These findings suggest that
cilostazol might have beneficial activity in the treatment of
neuropsychiatric diseases. By contrast, it has been reported that
mRNA levels of PDE3A and PDE3B were relatively low in the
human brain whereas mRNA levels of PDE3A were the highest in
the heart [18]. Thus, it is unlikely that PDE3 inhibition by
cilostazol would be a major contributing factor to its effects on the
brain.
The purpose of this study was to examine the precise
mechanisms underlying the beneficial effects of cilostazol. First,
we examined the effects of cilostazol and the other PDE3
inhibitors cilostamide and milrinone [19] on nerve growth factor
(NGF)-induced neurite outgrowth in PC12 cells, which has been
widely used as a model for studying neurite outgrowth [20–23].
In this study, we found that cilostazol, but not cilostamide or
milrinone, significantly potentiated NGF-induced neurite out-
growth. Second, we examined the precise cellular mechanisms
underlying the potentiation by cilostazol of NGF-induced
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17431neurite outgrowth. Finally, we identified that eukaryotic
translation elongation factor eEF1A1, one of the most abundant
protein synthesis factors [24], might be a novel target for
cilostazol.
Results
Effects of three PDE3 inhibitors on NGF-induced neurite
outgrowth in PC12 cells
Cilostazol (0.1, 1.0 or 10 mM) significantly increased the
number of cells with neurites induced by NGF (2.5 ng/ml), in a
concentration-dependent manner (Fig. 1). In contrast, cilostamide
(0.1, 1.0 or 10 mM) and milrinone (0.1, 1.0 or 10 mM) did not
increase the number of cells with NGF (2.5 ng/ml)-induced
neurites (Fig. 1). The microtubule-associated protein 2 (MAP-2)
immunocytochemistry showed that cilostazol (10 mM) but not
cilostamide (10 mM) increased the number of cells with NGF
(2.5 ng/ml)-induced neurites (Fig. S1). These findings suggest that
the inhibition of PDE3 does not contribute to the active
mechanism of cilostazol.
Role of signaling molecules proximal to TrkA in the
potentiation of NGF-induced neurite outgrowth by
cilostazol
We examined the effects of the specific inhibitors of PLC-c,
PI3K, Akt, p38 MAPK, and c-Jun N-terminal kinase (JNK), since
these signaling molecules are activated upon the addition of NGF
[20–23,25–27]. The PLC-c inhibitor (U73122; 1.0 mM), PI3K
inhibitor (LY294002; 10 mM), Akt inhibitor (1.0 mM), p38 MAPK
inhibitor (SB203580; 10 mM), and JNK inhibitor (SP600125;
10 mM) significantly blocked the potentiation of NGF-induced
neurite outgrowth by cilostazol (10 mM) (Fig. 2). In contrast, these
inhibitors alone did not alter NGF-induced neurite outgrowth in
PC12 cells (Fig. 2).
Role of the Ras/Raf/ERK/MAPK pathway in the
potentiation of NGF-induced neurite outgrowth by
cilostazol
The Ras/Raf/ERK/MAPK pathway is known to be involved
in NGF-induced neurite outgrowth [20,22,23,25,26]. Therefore,
we examined the effects of the pathway’s specific inhibitors. The
Ras inhibitor (GW5074; 1.0 mM), Raf inhibitor (lovastatin;
10 mM), MEK inhibitor (U0126; 10 mM), MEK1/2 inhibitor
(SL327; 10 mM), and MAPK inhibitor (PD98059; 10 mM)
significantly blocked the potentiation of NGF-induced neurite
outgrowth by cilostazol (10 mM) (Fig. 3). In contrast, U0124
(10 mM), an inactive analog of U0126, did not alter the
potentiation of NGF-induced neurite outgrowth by cilostazol
(Fig. 3). Furthermore, these inhibitors alone did not alter the NGF-
induced neurite outgrowth in PC12 cells (Fig. 3).
Role of IP3 receptors in the potentiation of NGF-induced
neurite outgrowth by cilostazol
Previously, we reported that the receptors of the endoplasmic
reticulum (ER) protein inositol 1,4,5-triphosphate (IP3) play a role
in the NGF-induced neurite outgrowth in PC12 cells [20–23]. To
investigate the role of IP3 receptors in cilostazol’s action on NGF-
induced neurite outgrowth, we examined the effects of xestos-
pongin C (a selective, reversible, and membrane-permeable
inhibitor of IP3 receptors) [28] on the effects of cilostazol on
NGF-induced neurite outgrowth. Co-administration of xestos-
pongin C (1.0 mM) significantly blocked the potentiation of NGF-
induced neurite outgrowth by cilostazol (10 mM) (Fig. 4).
Furthermore, administration of xestospongin C (1.0 mM) alone
Figure 1. Effects of cilostazol, cilostamide, and milrinone on NGF-induced neurite outgrowth in PC12 cells. Cilostazol, but not
cilostamide and milrinone, significantly increased the number of cells with neurite, in a concentration-dependent manner. Number is the
concentration (mM) of drugs. ***P,0.001 as compared with control (NGF (2.5 ng/ml) alone group). The data show the mean 6 SEM (n=6–16).
doi:10.1371/journal.pone.0017431.g001
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(Fig. 4).
Role of eEF1A1 in the potentiation of NGF-induced
neurite outgrowth by cilostazol
To determine the molecular target of cilostazol’s action on
NGF-induced neurite outgrowth, we performed two-dimensional
gel electrophoresis proteome analysis. We identified the eukaryotic
translation elongation factor eEF1A1 as showing different protein
levels in PC12 cells treated with cilostazol (10 mM) or cilostamide
(10 mM); namely, eEF1A1 protein was significantly increased by
the treatment with cilostazol but not by cilostamide (Fig. S2).
To determine whether eEF1A1 mediates the potentiation of
NGF-induced neurite outgrowth by cilostazol, we treated PC12
cells with eEF1A1 RNA interference (RNAi), which reduces the
expression of the eEF1A1 protein. As shown in Fig. 5A, the
increase of eEF1A1 protein by cilostazol (10 mM) was significantly
blocked by treatment with eEF1A1 RNAi, but not by the negative
control of eEF1A1 RNAi. In contrast, treatment with eEF1A1
RNAi or the negative control of eEF1A1 RNAi alone did not alter
the basal levels of eEF1A1 protein (Fig. 5A). Furthermore, the
potentiating effects of cilostazol (10 mM) on NGF-induced neurite
outgrowth were significantly antagonized by treatment with
eEF1A1 RNAi, but not by the negative control of eEF1A1
(Fig. 5B). In contrast, treatment with eEF1A1 RNAi or the
negative control of eEF1A1 RNAi alone did not alter the NGF-
induced neurite outgrowth in PC12 cells (Fig. 5B).
Discussion
The major findings of this study are that an increase in the
eEF1A1 protein by cilostazol might be involved in the mechanisms
of potentiation of NGF-induced neurite outgrowth by cilostazol.
First, we found that cilostazol, but not cilostamide or milrinone,
could potentiate NGF-induced neurite outgrowth in PC12 cells,
suggesting that inhibition of PDE3 by cilostazol might not be
involved in the active mechanism for potentiation of NGF-induced
neurite outgrowth by this drug. Second, the IP3 receptors and
several common cellular signaling pathways might be involved in
this action of cilostazol. Third, we identified eEF1A1 as a novel
target for cilostazol. To our knowledge, this is the first report
demonstrating that an increase in eEF1A1 protein by cilostazol is
required for cilostazol’s action on the neurite outgrowth.
Figure 2. Effects of the specific inhibitors of PLC-c, PI3K, Akt, p38MAPK, and JNK on potentiation of NGF-induced neurite
outgrowth by cilostazol. The potentiating effects of cilostazol (10 mM) on the NGF (2.5 ng/ml)-induced neurite outgrowth were antagonized by
co-administration of the PLC-c inhibitor (U73122; 1.0 mM), the PI3K inhibitor (LY294002; 10 mM), the Akt inhibitor (1.0 mM), the p38MAPK inhibitor
(SB203580; 10 mM), or the JNK inhibitor (SP600125; 10 mM). ***P,0.001 as compared with control (NGF (2.5 ng/ml) alone group). The data show the
mean 6 SEM (n=6–25).
doi:10.1371/journal.pone.0017431.g002
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several signaling pathways affecting both morphological and
transcriptional targets [20,22,23,25,26]. The signaling molecules,
including PLC-c, PI3K, Akt, p38 MAPK, and JNK, are activated
upon the addition of NGF [29]. PLC-c catalyzes the hydrolysis
of phosphatidylinositol-4,5-bisphosphate (PIP2) to diacylglycerol
(DAG) and IP3. DAG activates protein kinase C, and IP3 promotes
transient release of Ca
2+ from the ER via stimulation at the IP3
receptors. Thus, the pathway via PLC-c is responsible for NGF-
induced neurite outgrowth [20,22,23,30]. Furthermore, stimula-
tion of PI3K is reported to be involved in the promotion of neurite
outgrowth in PC12 cells [20,22,23,31]. In this study, we found that
the PLC-c inhibitor U73122, the PI3K inhibitor LY294002, and
an Akt inhibitor significantly blocked the potentiation of NGF-
induced neurite outgrowth by cilostazol. Moreover, we found that
both the p38MAPK inhibitor SB203580 and the JNK inhibitor
SP600125 significantly blocked the potentiation of NGF-induced
neurite outgrowth by cilostazol. Additionally, we found that the
specific inhibitors for the Ras/Raf/MEK/MAPK pathways
significantly blocked the potentiation of NGF-induced neurite
outgrowth by cilostazol. Taken together, these findings suggest
that common pathways, including PLC-c, PI3K, Akt, p38MAPK,
JNK and Ras/Raf/MEK/MAPK, are involved in the mecha-
nisms of cilostazol’s potentiation of NGF-induced neurite
outgrowth. The present results may be of special interest in
relation to the role of the PI3K/Akt/ERK/MAPK signaling
pathway in the control of protein synthesis-dependent learning
and memory [32].
It is known that IP3 is a ubiquitous second messenger
responsible for the release of Ca
2+ from the ER, and that control
of Ca
2+ by IP3 receptors on the ER is critically important in
maintaining a number of cellular functions, including cell growth,
neurite outgrowth [33,34]. Interestingly, it has been reported that
calcium signaling mediated by IP3 receptors resulted in neurite
outgrowth, suggesting that IP3-mediated Ca
2+ release from
internal stores is necessary to maintain [Ca
2+]i, within the
optimum range of neurite outgrowth [35]. In this study, we found
that the IP3 receptor antagonist xestospongin C significantly
blocked the potentiation of NGF-induced neurite outgrowth by
cilostazol, suggesting the role of IP3 receptors on NGF-induced
Figure 3. Effects of the specific inhibitors of Ras, Raf, MEK, MEK1/2, and MAPK on potentiation of NGF-induced neurite outgrowth
by cilostazol. The potentiating effects of cilostazol (10 mM) on the NGF-induced neurite outgrowth were antagonized by co-administration of the
Ras inhibitor (GW5074; 1.0 mM), the Raf inhibitor (lovastatin; 10 mM), the MEK inhibitor (U0126; 10 mM), the MEK1/2 inhibitor (SL327; 10 mM), and the
MAPK inhibitor (PD98059; 10 mM). In contrast, U0124 (10 mM), an inactive analog of U0126, did not alter the potentiation of NGF-induced neurite
outgrowth by cilostazol. **P,0.01, ***P,0.001 as compared with control (NGF (2.5 ng/ml) alone group). The data show the mean 6 SEM (n=6–14).
doi:10.1371/journal.pone.0017431.g003
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a role in the potentiation of NGF-induced neurite outgrowth by
sigma-1 receptor agonists (e.g., fluvoxamine, donepezil), the
ROCK inhibitor Y-27632 or the antibiotic drug minocycline
[20–23]. Together, it seems that stimulation at the IP3 receptors
on the ER is involved in the mechanism underlying the
potentiation of NGF-induced neurite outgrowth by cilostazol.
Protein synthesis (or translation) in eukaryotic cells is funda-
mental for gene expression and is tightly controlled by three
fundamental stages: translation, elongation, and termination
[24,36,37]. Translation elongation requires several proteins called
eukaryotic elongation factors (eEFs). Of these, eEF1A1 is one of
the most abundant protein synthesis factors, and is responsible for
the delivery of all aminoacyl-tRNAs to the ribosome, aside from
initiator and selenocysteine tRNAs [24]. In the present study, we
found that the increase in the levels of eEF1A1 protein by
cilostazol might play a role in the mechanism of potentiation of
NGF-induced neurite outgrowth by this drug although the precise
mechanisms underlying the cilostazol-induced increase of eEF1A1
are currently unclear. It has been reported that the levels of eEF1A
correlate with the rate of apoptosis upon serum withdrawal [38],
and that eEF1A promotes survival following growth factor
withdrawal [39], suggesting that eEF1A has neuroprotective
effects. Protein synthesis is also known to be necessary for neurite
outgrowth in PC12 cells [40]. Taken together, it is likely that
eEF1A families including eEF1A1 play a role in neurite
outgrowth, indicating that eEF1A1 may be a potential target for
developing therapeutic drugs for certain neurodegenerative and
psychiatric diseases. Therefore, agents that can increase the
eEF1A1 protein may have therapeutic relevance in diverse
conditions with altered neurite outgrowth.
Previously, we reported that an increase in the translation
initiation factors eIF4AI by the antibiotic drug minocycline might
play a role in the mechanisms of its action for NGF-induced
neurite outgrowth in PC12 cells [23]. However, we found that
cilostazol did not affect the levels of eIF4AI in PC12 cells
(Fig. S3). Therefore, it is likely that an increase of eEF1A1, but
not eIF4AI, by cilostazol plays a major role in the mechanism
of its action.
It is known that PDE3A had a strikingly selective distribution
with 10–15 fold higher levels in the human heart compared to any
other tissues and tenfold higher expression than any other PDEs in
the heart [18]. Furthermore, Sun et al. [41] reported that PDE3A
knockout mice were protected against collagen/epinephrine-
induced pulmonary thrombosis and death, and that these showed
an increased heart rate, suggesting that PDE3A plays a role in
regulating intracellular cAMP levels in the cardiovascular system.
Considering the beneficial effects of cilostazol on neurite
outgrowth, it is possible that cilostazol may have a potential
therapeutic activity in heart disease.
In conclusion, the present results suggest that cilostazol, but not
cilostamide and milrinone, could potentiate NGF-induced neurite
outgrowth in PC12 cells, and that interaction with IP3 receptors
and several cellular signaling pathways are involved in the
mechanism underlying the pharmacological action of cilostazol.
Furthermore, we identified eEF1A1 as a novel target for
mechanisms of action of cilostazol. These findings offer new
approaches to develop potential therapeutic drugs that can target
translation elongation factors including eEF1A1.
Materials and Methods
Drugs
The drugs were obtained from the following sources: cilostazol
(Otsuka Pharmaceutical Co., Ltd, Tokyo, Japan); cilostamide,
milrinone, xestospongin C (Wako Pure Chemicals Inc., Tokyo,
Japan); LY294002 (Sigma-Aldrich, St Louis, MO); NGF (Pro-
mega, Madison, WI); lovastatin, PD98059, GW5074, SB203580,
MEK 1/2 inhibitor (SL327), SP600125, U0126, U0124 (Calbio-
chem-Novabiochem, San Diego, CA), and Akt inhibitor (Bio
Vision Inc., CA). Other drugs were purchased from commercial
sources.
Cell culture
PC12 sells (RIKEN Cell Bank, Tsukuba, Japan) were cultured
at 37uC, 5% CO2 with Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 5% heat-inactivated fetal bovine
serum (FBS), 10% heat-inactivated horse serum, and 1%
penicillin. The medium was changed two or three times a week.
PC12 cells were plated onto 24-well tissue culture plates coated
with poly-D-lysine/laminin. Cells were plated at relatively low
density (0.25610
4 cells/cm
2) in DMEM medium containing 0.5%
FBS, 1% penicillin streptomycin. Medium containing a minimal
level of serum (0.5% FBS) was used as previously reported [22–
23]. Previously, we examined the optimal concentration of NGF
for NGF-induced neurite outgrowth in PC12 cells. NGF (2.5, 5,
10, 20, 40 ng/ml) increased the number of cells with neurite
outgrowth in PC12 cells, in a concentration-dependent manner
[20]. In the present studies, 2.5 ng/ml of NGF was used to study
the potentiating effects of PDE3 inhibitors on NGF-induced
neurite outgrowth. Twenty-four hours after plating, the medium
was replaced with DMEM medium containing 0.5% FBS and 1%
penicillin streptomycin with NGF (2.5 ng/ml) with or without
several drugs.
Quantification of neurite outgrowth
Four days after incubation with NGF (2.5 ng/ml) with or
without the several drugs, morphometric analysis was performed
on digitized images of live cells taken under phase-contrast
illumination with an inverted microscope linked to a camera.
Images of three fields per well were taken, with an average of 100
cells per field. Differentiated cells were counted by visual
examination of the field; only cells that had at least one neurite
Figure 4. Effects of the IP3 receptor antagonist on potentiation
of NGF-induced neurite outgrowth by cilostazol. The potentiat-
ing effects of cilostazol (10 mM) on the NGF-induced neurite outgrowth
were antagonized by co-administration of the selective IP3 receptor
antagonist xestospongin C (1.0 mM). In contrast, xestospongin C
(1.0 mM) alone did not alter NGF-induced neurite outgrowth. The data
show the mean 6 SEM (n=6–12). ***P,0.001 as compared with control
(NGF (2.5 ng/ml) alone group).
doi:10.1371/journal.pone.0017431.g004
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were then expressed as a percentage of the total cells in the field.
The counting was performed in a blinded manner.
Differential in two-dimensional gel electrophoresis and
MALDI-TOF MS analysis
In the presence of NGF (2.5 ng/ml), PC12 cells were treated
with cilostazol (10 mM), or cilostamide (10 mM). After four days,
cells were suspended in Laemmli lysis buffer, and two-dimensional
gel electrophoresis was performed. The spots of interest were
analyzed using MALDI-TOF MS (Voyager-DE STR, Applied
Biosystem, CA).
Western blot analysis
PC12 cells were washed with PBS and lysed in Laemmli lysis
buffer. Aliquots (30 mg) of the proteins were measured by DC
protein assay kit (Bio-Rad, Hercules, CA) and incubated for 5 min
at 95uC with an equal volume of 125 mM Tris/HCl, pH 6.8, 20%
glycerol, 0.1% bromphenol blue, 10% b-mercaptoethanol, 4%
SDS, and subjected to SDS-PAGE using 7.5% mini-gels (Mini
ProteanII; Bio-Rad, Hercules, CA). Proteins were transferred onto
PVDF membranes using a Trans Blot Mini Cell (Bio-Rad,
Hercules, CA). For immunodetection, the blots were blocked for
1 h in TBST (50 mM Tris/HCl, pH 7.8, 0.13 M NaCl, 0.1%
Tween 20) containing 5% nonfat dry milk at room temperature
(RT), followed by incubation with rabbit anti-eEF1A1 antibody
(1:250, ab37969, Abcam, Cambridge, UK) overnight at 4uCi n
TBST/5% blocker. The blots were washed five times with TBST.
Incubation with the secondary antibody (GE Healthcare Biosci-
ence, UK) was performed for 1 h at RT. After extensive washing,
immunoreactivity was detected by ECL plus Western Blotting
Detection system (GE Healthcare Bioscience, UK). Images were
captured using a Fuji LAS3000-mini imaging system (Fujifilm,
Tokyo, Japan) with the Multi Gauge software (Ver.3.0; Fujifilm,
Tokyo, Japan) and immunoreactive bands were quantified. b-actin
immunoreactivity was used to monitor equal sample loading.
RNAi transfection
RNAi gene expression knockdown studies were performed using
the TriFECTa RNAi kit (Integrated DNA Technologies, Coral-
ville, CA) and corresponding protocol. Each 27 mer RNAi
duplex was transfected into cells using Lipofectamine 2000
reagent (Invitrogen, Carlsbad, CA) following the manufacturer’s
guidelines. RNAi was purchased from Integrated DNA
Figure 5. Increase in eEF1A1 protein is required for cilostazol-induced potentiation of NGF-induced neurite outgrowth in PC12
cells. (A) The potentiating effects of cilostazol (10 mM) on the eEF1A1 protein levels were significantly antagonized by treatment of eEF1A1 RNAi, but
not negative RNAi. In contrast, eEF1A1 RNAi or negative RNAi alone did not alter the levels of eEF1A1 protein in the control (NGF (2.5 ng/ml)-treated)
group. The data show the mean 6 SEM (n=7–16). *p,0.05 as compared with cilostazol (10 mM) group. (B) The potentiating effects of cilostazol
(10 mM) on the NGF-induced neurite outgrowth were significantly antagonized by treatment of eEF1A1 RNAi, but not negative RNAi. In contrast,
eEF1A1 RNAi or negative RNAi alone did not alter NGF (2.5 ng/ml)-induced neurite outgrowth. The data show the mean 6 SEM (n=8). ***p,0.001 as
compared with cilostazol (10 mM) group.
doi:10.1371/journal.pone.0017431.g005
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Rattus norvegicus eukaryotic translation elongation factor
1A1 (Eef1a1), mRNA GenBank Accession No. NM_175838









Data are expressed as means 6 standard error of the mean
(SEM). Statistical analysis was performed by using one-way
analysis of variance (ANOVA) and the post hoc Bonferroni/Dunn
test. P values less than 0.05 were considered statistically significant.
Supporting Information
Figure S1 Effects of cilostazol and cilostamide on MAP-
2 immunocytochemistry in PC12 cells. Cells were fixed for
30 min at room temperature with 4% paraformaldehyde then
permeabilized with 0.2% Triton and blocked with 1.5% normal
goat serum, 0.1% bovine serum albumin (BSA) in 0.1 M
phosphate-buffer saline for 1 h to reduce nonspecific binding.
Cells were incubated overnight at 4uC with anti-microtubule-
associated protein 2 (MAP-2) antibodies (1:1000 dilution in
blocking solution, Chemicon International, Temecula, CA,
USA). The immunolabeling was visualized with secondary
antibodies conjugated to Alexa-488 (1:1000; Invitrogen, Carlsbad,
CA, USA). MAP-2 immuncytochemistry was visualized with a
fluorescence microscope (Axiovert 200, Carl Zeiss, Oberkocken,
Germany). Representative photographs of MAP-2 immunocyto-
chemistry in PC12 cells. (A) Control (NGF (2.5 ng/ml) alone) (B)
NGF+cilostazol (10 mM), (C) NGF+cilostamide (10 mM).
(EPS)
Figure S2 Effects of cilostazol and cilostamide on
eEF1A1 protein in PC12 cells. PC12 cells were treated with
control (NGF (2.5 ng/ml)), NGF (2.5 ng/ml)+cilostazol (10 mM)
or NGF (2.5 ng/ml)+cilostamide (10 mM) for four days. Then cells
were washed with PBS, and lysed in Laemmli lysis buffer. Western
blot analysis was performed using rabbit anti-eEF1A1 antibody
(1:250, ab37969, Abcam, Cambridge, UK). Levels of eEF1A1
protein in PC12 cells were significantly increased by cilostazol
(10 mM), but not cilostamide (10 mM). The data show the mean 6
SEM (n=24). **P,0.05, ***p,0.001 as compared with cilostazol
treated group.
(EPS)
Figure S3 Lack of cilostazol on eIF4AI protein in PC12
cells. PC12 cells were treated with control (NGF (2.5 ng/ml)) or
NGF (2.5 ng/ml)+cilostazol (10 mM) for four days. Then cells
were washed with PBS, and lysed in Laemmli lysis buffer. Western
blot analysis was performed using rabbit anti-eIF4AI antibody
(1:250, ab31217, Abcam, Cambridge, UK) as reported previously
[23]. Levels of eIF4AI protein in PC12 cells were not altered by
cilostazol (10 mM). The data show the mean 6 SEM (n=8).
(EPS)
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